Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA panel

JAMA

Volumn 296, Issue 7, 2006, Pages 827-843

  Hammer, Scott M ^a   Saag, Michael S ^b   Schechter, Mauro ^c   Montaner, Julio S G ^d   Schooley, Robert T ^e   Jacobsen, Donna M ^f   Thompson, Melanie A ^g   Carpenter, Charles C J ^h   Fischl, Margaret A ⁱ   Gazzard, Brian G ^j   Gatell, Jose M ^k   Hirsch, Martin S ^l   Katzenstein, David A ^m   Richman, Douglas D ⁿ   Vella, Stefano ^o   Yeni, Patrick G ^p   Volberding, Paul A ^q  

^a Box 82 ^*  (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f International AIDS Society USA   (United States)

^g AIDS Research Consortium   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BARCELONA   (Spain)

^l HARVARD MEDICAL SCHOOL   (United States)

^m STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^p BICHAT HOSPITAL   (France)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ANEMIA; CARDIOTOXICITY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; INSOMNIA; INSULIN RESISTANCE; KIDNEY DISEASE; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; NAUSEA; PHYSICIAN; PRIORITY JOURNAL; RASH; REVIEW; TERATOGENICITY;

EID: 33747122666     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.7.827     Document Type: Review

References (134)

1. Centers for Disease Control and Prevention. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30:305-308.
2. Centers for Disease Control and Prevention. Twenty-five years of HIV/AIDS-United States, 1981-2006. MMWR Morb Mortal Wkly Rep. 2006;55:585-589.
3. UNAIDS/WHO AIDS Epidemic Update: December 2005. Available at: http://www.unaids.org/epi/2005/doc/report.asp. Accessed: March 6, 2006.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
5. Emini EA. Protease inhibitors. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract L1.
6. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel.JAMA. 1996;276:146-154.
7. Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.
8. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in HIV-1 infection. Nature. 1995;373:117-122.
9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
10. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-629.
11. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA. 1998;279:1984-1991.
12. World Health Organization (WHO) Guidelines. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach. June 2006. http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf. Accessed November 13, 2003.
13. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251-265.
14. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.
15. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
16. National Institutes of Health. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ( JNC 7) Express. http://www.nhlbi.nih.gov/guidelines/hypertension/ express.pdf. Accessed February 3, 2006.
17. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
18. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected drug naive patients starting potent antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
19. Lichtenstein K, Armon C, Buchacz K, et al. Early, Uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV outpatient study (HOPS). In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 769.
20. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235-239.
21. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759.
22. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093-1097.
23. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770.
24. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Pregnancy outcomes after combined ART or short-course AZT with single-dose nevirapine in Thai women with high and low CD4 cell counts. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 712.
25. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
26. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
27. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three-vs four-drug antiretroviral regimen for the initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study-ACTG 5095): a randomized controlled trial. JAMA. 2006;296:769-781.
28. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
29. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapyassociated hyperbilirubinemia. J Infect Dis. 2005;192:1381-1386.
30. Persico M, Persico E, Bakker CT, et al. Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology. 2001;33:627-632.
31. Rodriguez Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42:291-295.
32. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from A1424-089. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Abstract 107LB.
33. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735-743.
34. Ananworanich J, Ruxrungtham K, Siangphoe U, et al. A prospective cohort study of efficacy and safety of 2 nRTIs plus once-daily ritonavir-boosted saquinavir hard gel capsule (SQV-HGC/R) at 24 weeks. In: Program and abstracts 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract Poster TuPeB4469.
35. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
36. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG A5095: a comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 41.
37. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
38. Sheran M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. HIV Clin Trials. 2005;6:158-168.
39. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101:4180-4185.
40. Rauch A, Nolan D, Martin A, Mckinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99-102.
41. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-189.
42. Cheng A, Wulfsohn M, Cheng SS, Toole JJ. 2 year long term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, doubleblind, placebo-controlled clinical trials. In: Program and abstracts of the 9th European AIDS Conference; October 25-29, 2003; Warsaw, Poland. Abstract 7.3/7.
43. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1198.
44. Thompson M, Haubrich R, Margolis D, et al. Differences in calculated glomerular filtration rates in efavirenz- or tenofovir-treated adults in ESS40006. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 777.
45. Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006; Denver, Colo. Abstract 778.
46. Heffelfinger J, Hanson D, Voetsch A, McNaghten A, Sullivan P. Renal impairment associated with the use of tenofovir. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 779.
47. Crane H, Harrington R, Van Rompaey S, Kitahata M. Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 780.
48. Nelson M, Cooper D, Schooley R, et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 781.
49. Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS. 2005;19:213-215.
50. Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis. 2005;41:901-905.
51. Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet. 2004;364:65-67.
52. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther. 2005;10:171-177.
53. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20:1391-1399.
54. Moyle G, Higgs C, Teague A, et al. An openlabel, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11:73-78.
55. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus; recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-629.
56. Rizzardi GP, de Boer RJ, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000;105:777-782.
57. Raboud JM, Rae S, Hogg RS, et al. Suppression of plasma viral load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347-1350.
58. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
59. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195-200.
60. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type I: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2003;37:113-128.
61. Wensing AMJ, van de Vijver DA, Angarano G, et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
62. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of inductionmaintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA. 2000;283:205-211.
63. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
64. International AIDS Society-USA Resistance Mutations Project Panel. Update of the drug resistance mutations in HIV-1. Available at: http://www.iasusa.org/ resistance_mutations/. Accessed: February 3, 2006.
65. Haubrich RH, Currier JS, Forthal DN, et al. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001;33:1060-1068.
66. Katlama C, Walmsley S, Hicks C, et al. Tipranavir achieves twice the rate of treatment responses and prolongs durability of response versus comparator PI in antiretroviral experienced patients, independent of baseline CD4+ cell count or viral load: week 48 RESIST 1 and 2 combined analyses. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006; Denver, Colo. Abstract 520.
67. Pozniak A, Saag M, Bellos N, et al. Efficacy of TMC114/r in treatment-experienced HIV patients: factors influencing outcome in the pooled 24-week analysis of POWER 1, 2, and 3. In: Program and abstracts of the 12th Annual Conference of the British HIV Association; March 29-April 1, 2006; Brighton, England. Abstract 3.
68. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment the SWAN Study: final results (48 weeks). In: Program and abstracts of the 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland.
69. Tavassoli N, Bagheri H, Sommet A, et al. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Pharmacotherapy. 2006;26:154-161.
70. Sension M, Grinsztejn B, Molina J, et al. Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. Abstract 858.
71. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment: planned week 24 analysis of a phase IIIb 48 week multicenter, open-label, randomized, prospective study, the SWAN study. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract Poster WePe6.3C15.
72. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412.
73. Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 157.
74. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
75. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as a single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
76. Swindells S, DiRienzo AF, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-814.
77. Ananworanich J, Gayet-Agernon A, Lebraz M, et al. CD4 guided scheduled treatment interruption compared to continuous therapy: Results of the Staccato Trial. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 102.
78. Marchou B, Tangre P, Charreau I, et al. Structured treatment interruptions in HIV-infected patients with high CD4 cell counts and virologic suppression: results of a prospective, randomized, openlabel trial (Window-ANRS 106). In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections: February 5-8, 2006; Denver, Colo. Abstract 104.
79. Danel C, Moh R, Sorho S, et al. The CD4-guided strategy arm stopped in a randomized structured treatment interruption trial in West-African adults: ANRS 1269 Trivacan Trial. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 105LB.
80. Palmisano L, Giuliano M, Bucciardini R, et al. Final results of a randomized, controlled trial of structured treatment interruptions vs continuous HAART in chronic HIV-infected subjects with persistent suppression of viral replication. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 103.
81. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 144.
82. 3. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 101.
83. Jacobson J, Saag MS. Evidence that intermittent structured treatment interruption (STI) promotes immunologic control of HIV replication: The results of AACTG 5068. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract Poster TuPe13.2B01.
84. Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-1137a.
85. Cahn P. 24-week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatmentexperienced HIV patients. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, Scotland. Abstract PL143.3.
86. Katlama C, Carvalho MT, Cooper D, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213). In Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
87. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the Power 2 Study (C202). In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract H-413.
88. Parkin NT, Chappey C. Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 637.
89. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006; Denver, Colo. Abstract 157.
90. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42:401-407.
91. Bonnet F, Balestre E, Bernardin E, Pellegrin JL, Neau D, Dabis F. Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999-2003. Antivir Chem Chemother. 2006;16:63-67.
92. Lo JC, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis. 2005;41:1335-1340.
93. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192:1537-1544.
94. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
95. Kitchen C, Suchard M, Lu J, Hoh R, Kuritzkes D, Deeks S. Continued GP41 evolution after interruption of enfuvirtide: evidence for ongoing immunologic pressure in advanced HIV disease. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections: February 5-8, 2006; Denver, Colo. Abstract 597.
96. Grabar S, Le Moing V, Goujard C, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. Acquir Immune Defic Syndr. 2005;39:284-292.
97. Nicastri E, Chiesi A, Angeletti C, et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol. 2005;76:153-160.
98. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS. 2006;20:371-377.
99. US Department of Health and Human Services and US. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed: February 21, 2006.
100. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:S21-S33.
101. Efavirenz capsules [package insert]. Bristol-Myers Squibb. http://www.sustiva.com. Accessed: Month 00, Accessed July 24, 2006.
102. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
103. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
104. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
105. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032-1035.
106. Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol. 2002;24:173-181.
107. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology. 2002;122:244-245.
108. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185-1192.
109. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis. 2004;39:1062-1064.
110. Benhamou Y, Fleury H, Trimoulet P, et al. Antihepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43:548-555.
111. Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother. 2002;46:1586-1588.
112. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002.
113. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferonribavirin combination treatment. Clin Infect Dis. 2005;41:1806-1809.
114. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis. 1999;180:666-672.
115. Currier JS, Spino C, Grimes J, et al; The AIDS Clinical Trials Group 175 Team. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. J Acquir Immune Defic Syndr. 2000;24:316-324.
116. Boehringer Ingelheim. Dear Health Care Professional [letter] . Germany: Boehringer Ingelheim Pharmaceuticals; 2004.
117. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-829.
118. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075-1083.
119. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.
120. Santos J, Palacios R, Gonzalvo A, Ruiz J, Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS. 2005;16:677-680.
121. Van Leth F, Phanupak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
122. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61:148-154.
123. Burger DM, Siebers MC, Hugen PW, Aarnoutse RE, Hekster YA, Koopmans PP. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101-102.
124. Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004;24:592-529.
125. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
126. Clark RA, Squires KE. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther. 2005;3:213-227.
127. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544.
128. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
129. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. http://www.cdc.gov/nchstp/tb/TB_HIV_Drugs/PDF/tbhiv.pdf. Accessed February 21, 2006.
130. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59:704-707.
131. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest. 2002;122:597-602.
132. Grinsztejn B, Nguyen BY, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 159LB.
133. DeJesus E, Berger D, Markowits M, et al. The HIV integrase inhibitor GS-9137 ( JTK-303) exhibits potent antiviral activity in treatment-naive and experienced patients. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 160LB.
134. Smith P, Forrest D, Beatty G, et al. Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 52.